Keyphrases
Myasthenia Gravis
100%
Musk
100%
Cellular Models
100%
Preclinical Animal Models
100%
Autoantibodies
40%
Neuromuscular Junction
20%
Muscle-specific Kinase Antibody
20%
Muscle Cells
10%
Muscle Weakness
10%
Neurologist
10%
Sample Size Calculation
10%
Acetylcholine Receptor (AChR)
10%
Neuromuscular Transmission
10%
Difficult-to-treat
10%
Clinical Disease
10%
Spontaneous Excitatory Postsynaptic Current (sEPSC)
10%
Culture Model
10%
Experimental Animals
10%
Miniature Endplate Potential
10%
Receptor Density
10%
Cells in Culture
10%
Synaptic Function
10%
Potential Therapy
10%
Kinase Function
10%
Passive Model
10%
Endplate Potential
10%
Antibody-mediated Disease
10%
Endplate Failure
10%
Activity-based Model
10%
Acetylcholine Receptor Clusters
10%
INIS
animals
100%
muscles
100%
tyrosine
100%
guidelines
100%
kinases
100%
antibodies
21%
diseases
14%
patients
14%
therapy
14%
receptors
14%
potentials
14%
design
14%
junctions
14%
acetylcholine
14%
increasing
7%
size
7%
reviews
7%
mice
7%
failures
7%
amplitudes
7%
transmission
7%
data analysis
7%
Neuroscience
Receptor Tyrosine Kinase
100%
Tyrosine Kinase
100%
Myasthenia gravis
100%
Autoantibodies
33%
Cholinergic Receptor
16%
Neuromuscular Junction
16%
Neuromuscular Transmission
8%
Miniature Endplate Potential
8%
Biochemistry, Genetics and Molecular Biology
Receptor Tyrosine Kinase
100%
Tyrosine Kinase
100%
Autoantibodies
33%
Acetylcholine Receptor
16%
Experimental Animal
8%
Sample Size
8%
Muscle Fiber Culture
8%
Miniature Endplate Potential
8%
Neuromuscular Transmission
8%
Endplate Potential
8%
Pharmacology, Toxicology and Pharmaceutical Science
Protein Tyrosine Kinase
100%
Myasthenia gravis
100%
Autoantibodies
33%
Cholinergic Receptor
16%
Diseases
16%
Experimental Animal
8%
Muscle Weakness
8%
Weakness
8%